Combining HER2 and EGFR with EpCAM in circulating tumor cell enrichment strategies enhances the capture of heterogeneous CTC populations, addressing the limitations of solely relying on EpCAM-based methods. The gene discussed is ERBB2; the disease is neoplasm.